HER-2-positive breast cancer: hope beyond trastuzumab. Biodrugs 2007; 21(2): 69–77Bartsch R, Wenzel C, Zielinski CC, Steger GG. HER-2-positive breast cancer: hope beyond trastuzumab. BioDrugs. 2007;21:69–77.Bartsch R, Wenzel C, Zielinski CC, et al.: HER-2-positive breast cancer:...
[4] Smith I, Procter M, Gelber RD, et al. HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial[J]. Lancet,2007,369(9555):29-36. [5] Perez EA, Romond...
“HER2 expression identifies dynamic functional states within circulating breast cancer cells.” Nature vol. 537,7618 (2016): 102-106. doi:10.1038/nature19328 Rugo, Hope S et al. “Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase...
10. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive,trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 20...
aTo accompany you in the morning, afternoon shopping with friends, she wanted to buy clothes, I'm her staff 要伴随您早晨,下午购物与朋友,她想买衣裳,我是她的职员[translate] aAughst Aughst[translate] aA case of HER-2-positive recurrent breast cancer 她2正面周期性乳腺癌病例[translate]...
Rugo, Hope S et al. “Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.” JAMA oncology vol. 7,4 (2021): 573-584. doi:10.1001/jamaoncol.2020.7932 ...
INTERLABORATORY CONCORDANCE IN HER-2 POSITIVE BREAST CANCER. Accurate assessment of HER-2 status is essential for identifying patients who will benefit from HER-2 targeted therapy. The aim of the present study was to... Nives,Jonji?,Elvira,... - 《Acta Clinica Croatica》 被引量: 2发表: ...
Eighty five percent (17/20) of patients with brain metastasis were HER2 positive compared with 40% (24/60) of HER-2 positivity in patients without brain metastases (with and without visceral metastasis) (p = 0.001). Concidering other metastatic sites, the probability of being HER2 positive ...
[1] GIANNI L, PIENKOWSKI T, IM Y H, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6...
2. Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis 3. Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women With Locally Advanced, Inflammatory, or Early HER2-positive Breast Cancer (NeoSphere): A Randomised Multicentre, Ope...